Key Points
- CEO Jeffrey Hawkins sold 20,143 Quantum-Si shares at an average price of $0.76, totaling $15,308.68. After the sale, he retained 3,649,659 shares, representing a 0.55% reduction in his position.
- Quantum-Si shares opened at $0.76, near their 50-day average of $0.77, with a market capitalization of approximately $166 million. The stock has traded between $0.69 and $3.10 over the past year.
- Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $1.00. The company recently reported a quarterly loss of $0.11 per share and $0.34 million in revenue.
Quantum-Si Incorporated (NASDAQ:QSI - Get Free Report) CEO Jeffrey Hawkins sold 20,143 shares of the company's stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $0.76, for a total value of $15,308.68. Following the completion of the sale, the chief executive officer owned 3,649,659 shares in the company, valued at $2,773,740.84. This trade represents a 0.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Jeffrey Alan Hawkins also recently made the following trade(s):
- On Tuesday, September 22nd, Jeffrey Hawkins sold 9,709 shares of Quantum-Si stock. The stock was sold at an average price of $0.76, for a total value of $7,378.84.
Quantum-Si Price Performance
Quantum-Si stock opened at $0.76 on Thursday. The stock's 50 day moving average is $0.77 and its 200 day moving average is $0.88. The firm has a market cap of $166.06 million, a P/E ratio of -1.65 and a beta of 3.25. Quantum-Si Incorporated has a one year low of $0.69 and a one year high of $3.10.
Quantum-Si (NASDAQ:QSI - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). The business had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.30 million. Quantum-Si had a negative net margin of 6,138.26% and a negative return on equity of 47.12%. Equities analysts anticipate that Quantum-Si Incorporated will post -0.47 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
QSI has been the subject of several recent analyst reports. Weiss Ratings cut shares of Quantum-Si from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, September 9th. Alliance Global Partners reaffirmed a "buy" rating on shares of Quantum-Si in a research report on Friday, August 14th. Finally, Wall Street Zen upgraded Quantum-Si from a "sell" rating to a "hold" rating in a report on Saturday, September 12th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Quantum-Si has a consensus rating of "Hold" and an average price target of $1.00.
Read Our Latest Analysis on QSI
Institutional Trading of Quantum-Si
Several hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new position in shares of Quantum-Si during the 1st quarter valued at $91,000. Corient Private Wealth LP acquired a new stake in Quantum-Si in the second quarter worth $34,000. WINTON GROUP Ltd bought a new stake in Quantum-Si in the second quarter valued at $67,000. IPG Investment Advisors LLC acquired a new position in shares of Quantum-Si during the second quarter valued at about $27,000. Finally, Green Alpha Advisors LLC acquired a new position in shares of Quantum-Si during the second quarter valued at about $41,000. Institutional investors own 39.90% of the company's stock.
Quantum-Si Company Profile
(
Get Free Report)
Quantum-Si Incorporated (NASDAQ:QSI) is a life sciences technology company focused on advancing proteomics, the study of proteins and their roles in biological systems. The company develops tools intended to help researchers identify and analyze proteins at the single-molecule level, supporting applications in drug discovery, translational research and precision medicine.
Its primary offering is the Platinum platform, which combines an automated instrument, proprietary sequencing technology, consumables and software for protein analysis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
